SpeeDx receives TGA clearance PlexPCR® SARS-CoV-2

SpeeDx Pty. Ltd. announced today their PlexPCR® SARS-CoV-2* test received clearance from the Australian Therapeutic Goods Administration (TGA). Designed from a database of over 1,000,000 sequences, the two gene, single-well test detects all current circulating variants§ of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the causative agent of COVID-19

“We have been supporting labs around the world with their COVID-19 test needs, and we are very happy to now extend that service to our local healthcare providers,” said Colin Denver, SpeeDx CEO.

Read the full press release